Skip to Main content Skip to Navigation
Journal articles

Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype

Abstract : Colorectal cancers (CRC) can be classified into four consensus molecular subtypes (CMS), among which CMS1 has the best prognosis, contrasting with CMS4 that has the worst outcome. CMS4 CRC is notoriously resistant against therapeutic interventions, as demonstrated by preclinical studies and retrospective clinical observations. Here, we report the finding that two clinically employed agents, everolimus (EVE) and plicamycin (PLI), efficiently target the prototypic CMS4 cell line MDST8. As compared to the prototypic CMS1 cell line LoVo, MDST8 cells treated with EVE or PLI demonstrated stronger cytostatic and cytotoxic effects, increased signs of apoptosis and autophagy, as well as a more pronounced inhibition of DNA-to-RNA transcription and RNA-toprotein translation. Moreover, nontoxic doses of EVE and PLI induced the shrinkage of MDST8 tumors in mice, yet had only minor tumor growth-reducing effects on LoVo tumors. Altogether, these results suggest that EVE and PLI should be evaluated for their clinical activity against CMS4 CRC.
Document type :
Journal articles
Complete list of metadata

https://hal.sorbonne-universite.fr/hal-03407503
Contributor : Hal Sorbonne Université Gestionnaire Connect in order to contact the contributor
Submitted on : Thursday, October 28, 2021 - 2:49:28 PM
Last modification on : Wednesday, November 17, 2021 - 12:34:05 PM

File

s41419-021-04270-x.pdf
Publication funded by an institution

Identifiers

Citation

Jiayin Deng, Ai-Ling Tian, Hui Pan, Allan Sauvat, Marion Leduc, et al.. Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype. Cell Death and Disease, Nature Publishing Group, 2021, 12 (11), ⟨10.1038/s41419-021-04270-x⟩. ⟨hal-03407503⟩

Share

Metrics

Record views

25

Files downloads

31